Phase 2 Parkinson's Disease Trial, Recruiting NCT07154511 Sponsor: Prabesh Kanel Condition: Parkinson's Disease
Back to Parkinsons Disease

Phase 2 Parkinson's Disease Trial, Recruiting

NCT07154511
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 45 years old or older, of any gender.
  • You have been diagnosed with Parkinson's disease with mild memory or thinking difficulties, OR with Parkinson's disease dementia, based on recognised medical diagnostic guidelines.
  • If you currently take certain medications (such as cholinesterase inhibitors, benzodiazepines, memantine, or anti-psychotic drugs), your dose has not changed in the past 4 weeks.

Who may not be able to join:

  • You have been diagnosed with an atypical form of parkinsonism (a Parkinson's-like condition that is not standard Parkinson's disease).
  • You are unable to have an MRI scan — for example, because you have a pacemaker, certain metal implants (such as aneurysm clips, metal in the eye, or a cochlear implant), or severe claustrophobia.
  • An MRI scan has shown signs of a large stroke or a growth/lesion in your brain.
  • You regularly take a type of medication known as "typical anti-cholinergic drugs" (confirm with trial site).
  • You have a recent history of a significant, uncontrolled gut or digestive condition, such as severe acid reflux (GERD) or colorectal cancer.
  • You have a significant metabolic condition or another serious medical condition that is not well controlled (confirm with trial site).
  • You are currently pregnant or breastfeeding.
  • You have had recent thoughts of suicide, as identified by a specific score on a standard questionnaire used by the trial team.
  • You have any other condition that the trial team believes would make it unsafe or unsuitable for you to take part.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Prabesh Kanel, PhD, University of Michigan

Phone: 734-936-1168

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Prabesh Kanel
Registry
ClinicalTrials.gov
Start date
7 November 2025
Est. completion
1 May 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Single composite global cognitive z-score; Movement Disorder Society Unified Parkinson's Disease Rating Scale Part III Score; Safety and tolerability of tributyrin

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov